Comparison of children and young people admitted with SARS-CoV-2 across the UK in the first and second pandemic waves: prospective multicentre observational cohort study

Competing Interest Statement

CJF reports no competing interests during the conduct of the study; but reports a Medical Research Council (MRC) Clinical Research Training Fellowship, outside the submitted work. JKB reports institutional grants from DHSC National Institute of Health Research UK (NIHR UK) and UK Research and Innovation (UKRI), during the conduct of the study; but reports no competing interests outside the submitted work. JSN-V-T reports no competing interests during the conduct of the study; but reports secondment to the Department of Health and Social Care, England (DHSC). JSN-V-T is an official Observer at, but not a member of, the Joint Committee for Vaccination and Immunisation (JCVI). The views expressed in this manuscript are those of its authors and not necessarily those of DHSC or the JCVI. LT reports no competing interests during the conduct of the study; but reports payment to the University of Liverpool from Eisai ltd for a lecture on COVID and cancer, outside of the submitted work. MGS reports grants from National Institute of Health Research UK (NIHR), Medical Research Council UK (MRC) and Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool, during the conduct of the study; and is chair of the Infectious Diseases Science Advisory Board and minority owner of Integrum Scientific, Greensboro NC, outside the submitted work. PJMO reports grant support from Institute of Health Research UK (NIHR) and Medical Research Council UK (MRC), during the conduct of the study; and reports collaborative grant support for EMINENT consortium from MRC/GSK and payment to Imperial College from Affnivax, Oxford Immunotech, Nestle and Pfizer, outside of the conduct of the study. PJMO reports payment to Imperial College London by Jansen (J&J) for chairing a symposium and delivering a lecture. PJMO was Past President of British Society for Immunology (unpaid), outside of the conduct of the study. SNF reports a grant (NIHR Senior Investigator Award) to his institution from National Institute of Health Research UK (NIHR), during the conduct of the study; and has been a clinical trial investigator on behalf of institution for Pfizer, Sanofi, GSK, J&J, Merck, AstraZeneca and Valenva, outside of the conduct of the study. No personal payments of any kind were given for these. SNF also reports institutional fees for speaking at a symposiums for Pfizer for meningococcal vaccines (2018 and 2019) and pneumococcal vaccines (2021); as well as institutional fees for advisory board participation for AstraZeneca, Medimmune, Sanofi, Pfizer, Seqirus, Sandoz, Merck and J&J. SNF was also Chair of UK NICE Sepsis (2014-16) and Lyme Disease (2016-18) Guidelines (adults and children) with expenses paid in line with NICE financial regulations. TMD reports no competing interests during the conduct of the study; but reports grant funding to institution for Aligos therapeutics for work on hepatobiliary cancer, outside of the conduct of the study. All other authors declare no competing interests.

Clinical Trial

ISRCTN66726260

Clinical Protocols

https://isaric4c.net/protocols/

Funding Statement

This work is supported by grants from the National Institute for Health Research (award CO-CIN-01) and the Medical Research Council (grant MC_PC_19059) and by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford (NIHR award 200907), Wellcome Trust and Department for International Development (215091/Z/18/Z), and the Bill and Melinda Gates Foundation (OPP1209135). Liverpool Experimental Cancer Medicine Centre provided infrastructure support for this research (grant reference: C18616/A25153). JSN-V-T is seconded to the Department of Health and Social Care, England (DHSC). The views expressed are those of the authors and not necessarily those of the DHSC, DID, NIHR, MRC, Wellcome Trust, or PHE.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Legal basis for data collection and ethics approval. In England and Wales routine anonymised data from medical records was collected without the need for consent under regulation 3 (4) of the Health Service (Control of Patient Information) Regulations 2002. In Scotland, a waiver of need for consent was obtained from the Public Benefit and Privacy Panel. Ethical approval was given by the South Central Oxford C Research Ethics Committee in England (reference 13/SC/0149) and the Scotland A Research Ethics Committee (reference 20/SS/0028).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes